Abstract: Objective  To investigate the expression level of stanniocalcin1(STC1) in serum of patients with renal cell carcinoma(RCC) and to reveal its potential clinical significance. 
Methods  Real-time polymerase chain reaction(Real-time, PCR) and enzyme-linked immunosorbent assay(ELISA) methods were used to measure the mRNA and protein expression level of STC1 in RCC（test group） and  the healthy person(control group). Then analyzed retrospectively the relationship between STC1 mRNA expression in peripheral blood of renal cell carcinoma patients and the clinical pathological parameters and follow-up results. Kaplan-Meier method was used to draw survival curve and tested by the log-rank test. 
Results  The mRNA and protein expression level of STC1 in serum of patients with renal cell carcinoma was higher than that of the control group(P＜0.01). The high expression of STC1 was associated with the clinical symptoms, histology type, tumor necrosis, late clinical stage, and lymphatic and distant metastasis are closely related(P＜0.05), Patients with high STC1 expression have a poor prognosis. 
Conclusion  STC1 is highly expressed in the serum of renal cell carcinoma patients, and its expression level is closely related to the clinical pathological parameters and poor prognosis of renal cell carcinoma. The increase of STC1 may have certain clinical value for the prognosis of renal cell carcinoma patients. 

Key words: kidney neoplasms, pathology, clinical, Stanniocalcin1